 Royalty Pharma and OMERS Capital Markets OMERS recently committed 350 million in non-dilutive funding for BioCryst. BioCryst generated 120 million from their flagship product Orladeyo in FY2021 and raised guidance to a minimum of 250 million for FY2022. 